AC Immune SA
(NASDAQ : ACIU)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 1.10%162.160.7%$1254.93m
PFEPfizer Inc. 2.47%38.530.9%$1060.23m
MRKMerck & Co., Inc. 1.03%77.450.7%$958.24m
ABBVAbbVie, Inc. 1.02%107.981.9%$778.70m
BMYBristol-Myers Squibb Co. 1.54%65.431.0%$758.06m
LLYEli Lilly & Co. 1.76%189.201.1%$575.67m
AZNAstraZeneca Plc -0.18%50.741.2%$463.76m
GSKGlaxoSmithKline Plc 0.21%37.770.2%$217.86m
NVSNovartis AG 0.95%88.030.2%$157.01m
RPRXRoyalty Pharma Plc 0.53%41.870.2%$143.72m
VTRSViatris, Inc. 0.90%13.400.0%$127.48m
CVACCureVac NV 5.04%109.290.0%$96.11m
RGENRepligen Corp. -0.13%213.306.8%$86.07m
NVONovo Nordisk A/S 0.95%72.190.1%$62.10m
SNYSanofi 1.20%51.300.2%$61.19m

Company Profile

AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.